Clinical Trials Browser

Phase 1 × Vorinostat × Sarcoma × Clear all

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

NCT04308330 2023-10-26

NYMC195

Phase 1 Unknown

30 enrolled

CNSGastrointestinalGenitourinarySarcoma

Neoplasms, Germ Cell and Embryonal, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Hepatoblastoma

NCT00217412 2014-06-17

Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia

Phase 1 Completed

60 enrolled

CNSLymphoidOther hematologic neoplasmSarcoma

Burkitt Lymphoma, Medulloblastoma, Neuroblastoma, Recurrence, Lymphoma, Large B-Cell, Diffuse, Rhabdoid Tumor, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myelomonocytic, Juvenile, Dendritic Cell Sarcoma, Interdigitating

NCT00994500 2013-07-02

Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma

Phase 1 Completed

20 enrolled

CNSLymphoidSarcoma

Familial ependymoma, Astrocytoma, Burkitt Lymphoma, Medulloblastoma, Meningioma, Oligodendroglioma, Recurrence, Lymphoma, Large B-Cell, Diffuse, Choroid Plexus Neoplasms, Lymphoma, Large-Cell, Anaplastic, Optic Nerve Glioma, Lymphoma, Extranodal NK-T-Cell, Dendritic Cell Sarcoma, Interdigitating

Clinical Trials

Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas

NYMC195

Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia

Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma